激素替代治疗对异基因造血干细胞移植后骨量的影响
该回顾性队列纳入234例2009年4月至2016年4月在韩国首尔圣母医院接受异基因造血干细胞移植后早发性卵巢功能不全的女性患者,评估激素替代治疗(HRT)对骨密度(BMD)的影响。HRT组(n=170)在治疗第1年和第2年腰椎BMD较非HRT组(n=64)显著升高(P=.033和P=.047)。结论支持早期积极激素治疗可能对女性HSCT受者的BMD有益。
要点
- HRT组腰椎BMD在治疗1年和2年时均显著高于非HRT组(P=.033和P=.047)。
- HRT组腰椎BMD较基线在1年和2年时分别增加4.16±4.39%和5.42±5.86%(P=.037和P=.021)。
- 移植后12个月内启动HRT者,治疗2年后腰椎BMD增幅最大。
核心结论
- 结果支持早期和积极的激素治疗可能对接受异基因HSCT后发生POI的女性受者BMD有益。
研究设计与样本
- 回顾性队列研究,纳入2009年4月至2016年4月在韩国首尔圣母医院接受异基因HSCT的234例女性POI患者。
- 纳入标准为移植时年龄40岁或以下且HSCT后随访至少3年的成人患者。
主要发现
- HRT组(n=170)在HRT后第1年和第2年腰椎BMD较非HRT组(n=64)显著升高(P=.033和P=.047)。
- HRT组腰椎BMD较基线在HRT 1年和2年后分别显著增加4.16±4.39%和5.42±5.86%(P=.037和P=.021)。
- HRT 2年后股骨颈和全髋BMD较基线也显示显著百分比增加。
- 这些变化在存在移植物抗宿主病或类固醇暴露时仍显著。
- HSCT后12个月内启动HRT者,HRT 2年后腰椎BMD增加最大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT AND OBJECTIVES: This study aimed to assess the effects of hormone replacement therapy (HRT) on bone mineral density (BMD) in young women who underwent allogeneic hematopoietic stem cell transplantation (HSCT). PARTICIPANTS AND METHODS: This retrospective cohort included 234 female patients with premature ovarian insufficiency (POI) who underwent allogeneic HSCT between April 2009 and April 2016 at Seoul St. Mary's Hospital in Seoul, Korea. Inclusion criteria included adult patients who were age 40 years or younger at the time of transplantation and were followed for at least 3 years after HSCT. RESULTS: At the first and second years after HRT, there was a significant increase in the BMD of the lumbar spine of the HRT group (n = 170) compared to that of the non-HRT group (n = 64) (P = .033 and P = .047, respectively). The BMD of the lumbar spine significantly increased from baseline by 4.16 ± 4.39% and 5.42 ± 5.86% after 1 and 2 years of HRT, respectively (P = .037 and P = .021). The BMD of the femoral neck and total hip also showed a significant percentage increase from baseline after 2 years of HRT. These changes were significant even in the presence of graft-versus-host disease or steroid exposure. For HRT that was initiated within 12 months after HSCT, the increase in BMD in the lumbar spine was greatest after 2 years of HRT. CONCLUSIONS: These results support that early and active hormonal therapy might be beneficial for BMD in female HSCT recipients with POI.
引用
- Ha J, Park SS, Park S, et al. Effects of Hormone Replacement Therapy on Bone Mass After Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Endocrinol Metab. 2020. PMID: 32594134. doi:10.1210/clinem/dgaa406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。